Payment overview · 2025
General Payments
$1,459.86
87 reported records · 18 companies
Healthcare provider profile · identity verified
Sudhirkumar C Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENVILLE, SC · NPI 1962590539
Verified facts
What the public records show
CMS Open Payments records show Sudhirkumar C Patel, M.D. received $1,459.86 in general payments during 2025 across 87 reported records.
Novo Nordisk Inc accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Tresiba.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $276.72 | 19.0% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.75 | 17.1% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.71 | 9.8% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $123.87 | 8.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.99 | 7.9% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $108.89 | 7.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.15 | 5.9% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $75.70 | 5.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.22 | 3.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.42 | 2.4% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $32.51 | 2.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $31.67 | 2.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.66 | 1.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.52 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.91 | 1.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18.64 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.42 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.11 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,459.86 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $227.93 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $197.76 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $163.48 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.95 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.83 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $108.89 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.86 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $79.86 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.70 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $75.70 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.59 | 5 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $67.40 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.44 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.22 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.39 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.01 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $32.51 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.58 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.06 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 12 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 278 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 169 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 188 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 36 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 142 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 229 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 15 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
| Tresiba tresiba |
2025 | Tresiba | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
169 | 36 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
229 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 316 |
| Amlodipine Besylate | Amlodipine Besylate | 840 | 258 |
| Losartan Potassium | Losartan Potassium | 615 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 176 |
| Omeprazole | Omeprazole | 576 | 187 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 538 | 172 |
| Metformin Hcl | Metformin Hcl | 516 | 162 |
| Carvedilol | Carvedilol | 455 | 128 |
| Pravastatin Sodium | Pravastatin Sodium | 430 | 132 |
| Lisinopril | Lisinopril | 405 | 125 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 115 |
| Gabapentin | Gabapentin | 304 | 93 |
| Ezetimibe | Ezetimibe | 295 | 103 |
| Eliquis | Apixaban | 278 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 92 |
| Ozempic | Semaglutide | 229 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 219 | 71 |
| Furosemide | Furosemide | 202 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 58 |
| Trazodone Hcl | Trazodone Hcl | 199 | 60 |
| Metformin Hcl Er | Metformin Hcl | 190 | 61 |
| Jardiance | Empagliflozin | 188 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 174 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 62 |
| Farxiga | Dapagliflozin Propanediol | 169 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 54 |
| Meloxicam | Meloxicam | 155 | 100 |
| Potassium Chloride | Potassium Chloride | 149 | 59 |
| Nifedipine Er | Nifedipine | 146 | 48 |
| Mounjaro | Tirzepatide | 142 | 28 |
| Mirtazapine | Mirtazapine | 141 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 41 |
| Allopurinol | Allopurinol | 125 | 46 |
| Famotidine | Famotidine | 121 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 37 |
| Spironolactone | Spironolactone | 114 | 41 |
| Nebivolol Hcl | Nebivolol Hcl | 113 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 111 | 34 |
| Chlorthalidone | Chlorthalidone | 109 | 38 |
| Sertraline Hcl | Sertraline Hcl | 109 | 36 |
| Irbesartan | Irbesartan | 108 | 30 |
| Torsemide | Torsemide | 105 | 51 |
| Azelastine Hcl | Azelastine Hcl | 100 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 64 |
| Finasteride | Finasteride | 93 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 30 |
| Donepezil Hcl | Donepezil Hcl | 86 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 23 |
| Simvastatin | Simvastatin | 82 | 25 |
| Glimepiride | Glimepiride | 81 | 25 |
| Montelukast Sodium | Montelukast Sodium | 81 | 27 |
| Valsartan | Valsartan | 80 | 25 |
| Januvia | Sitagliptin Phosphate | 79 | 18 |
| Ketoconazole | Ketoconazole | 78 | 57 |
| Prednisone | Prednisone | 74 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 28 |
| Azithromycin | Azithromycin | 72 | 64 |
| Methylprednisolone | Methylprednisolone | 66 | 61 |
| Benazepril Hcl | Benazepril Hcl | 65 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 25 |
| Mupirocin | Mupirocin | 62 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 58 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 39 |
| Celecoxib | Celecoxib | 53 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 51 |
| Tradjenta | Linagliptin | 52 | 16 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Meclizine Hcl | Meclizine Hcl | 51 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 49 | 14 |
| Colchicine | Colchicine | 48 | 25 |
| Bupropion Hcl | Bupropion Hcl | 46 | 16 |
| Cephalexin | Cephalexin | 44 | 32 |
| Memantine Hcl | Memantine Hcl | 41 | 14 |
| Ramipril | Ramipril | 41 | 12 |
| Telmisartan | Telmisartan | 40 | 14 |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 15 |
| Alendronate Sodium | Alendronate Sodium | 37 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 37 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Linzess | Linaclotide | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 30 |
| Novolog Flexpen | Insulin Aspart | 30 | 15 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 24 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 11 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 15 |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Methocarbamol | Methocarbamol | 20 | 12 |
| Atenolol | Atenolol | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 15 |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Metronidazole | Metronidazole | 12 | 12 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,459.86 · 87 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CREON, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INJECTAFER, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tresiba, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error